Serum Proteins as Drug Carriers of Anticancer Agents: A Review

References

• Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol 1996; 263: 32–60
   PubMed Web of Science ®Google Scholar
• Allen T. M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial. FEBS Lett 1987; 223: 42–46
   PubMed Web of Science ®Google Scholar
• Anderson R. G. W., Brown M. S., Goldstein J. L. Inefficient internalization of receptor-bound low density lipoprotein in human carcinoma A-431 cells. J. Cell Biol 1981; 88: 441–452
   PubMed Web of Science ®Google Scholar
• Andersson C., Iresjo B. M., Lundholm K. Identification of tumor sites for increased albumin degradation in sarcoma-bearing mice. J. Surg. Res 1991; 50: 156–162
   PubMed Web of Science ®Google Scholar
• Aulbert E. Transferrinmangelänamie bei malignen Tumorerkrankungen. Georg Thieme Verlag Stuttgart, New York 1986
   Google Scholar
• Babson A. L., Winnick T. Protein transfer in tumor-bearing rats. Cancer Res 1954; 14: 606–611
   PubMed Web of Science ®Google Scholar
• Bailey S., Evans R. W., Garrat R. C., Gorinsky B., Hasnain S., Horsburgh C., Jhoti H., Lindley P. F., Mydin A., Sarra R., Watson J. L. Molecular structure of serum transferrin at 3.3 Å resolution. Biochemistry 1988; 27: 5804–5812
   PubMed Web of Science ®Google Scholar
• Barabas K., Sizensky J. A., Faulk W. P. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA. J. Biol. Chetn 1992; 267: 9437–9442
   PubMed Web of Science ®Google Scholar
• Bejaoui N., Page M., Noel C. Cytotoxicity of transferrin-daunorubicin conjugates. Anticancer Res 1991; 11: 2211–2213
   PubMed Web of Science ®Google Scholar
• Bergamaschi G., Cazzola M., Dezza L., Savino E., Consonni E., Lappi D. Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). Br. J. Haematol 1988; 68: 379–384
   PubMed Web of Science ®Google Scholar
• Beyer U., Roth T., Schumacher P., Maier G., Unold A., Frahm A. W., Fiebig H. H., Unger C., Kratz F. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil. J. Med. Chem 1998; 41: 2701–2708
   PubMed Web of Science ®Google Scholar
• Bostik J., Bures L., Spundova M., Rehak L. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. IV. Therapy of murine melanona B16 by human serum albumin-methotrexate. Neoplasma 1988; 35: 343–349
   PubMed Web of Science ®Google Scholar
• Brock J. H. Transferrins. Metalloproteins, Part 2: Metal Proteins with Nonredox Roles, P. M. Harrison. Verlag Chemie, Weinheim 1985; 183–263
   Google Scholar
• Bures L., Bostik J., Motycka K., Spundova M., Rehak L. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing. Neoplasma 1988; 35: 329–342
   PubMed Web of Science ®Google Scholar
• Bures L., Lichy A., Bostik J., Spundova M. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy V. Alternative methods for preparation of serum albumin-methotrexate derivative. Neoplasma 1990; 37: 225–231
   PubMed Web of Science ®Google Scholar
• Butler T. P., Grantham F H., Gullino P. M. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 1975; 35: 3034–3088
   Google Scholar
• Cantafora A., Blotta I. Neutral lipids production, transport, utilization. Anticancer Res 1996; 16: 1441–1450
   PubMed Web of Science ®Google Scholar
• Cazzola M., Bergamaschi G., Dezza L., Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: Achievements and prospects. Blood 1990; 75: 1903–1919
   PubMed Web of Science ®Google Scholar
• Chitambar C. R., Seligman P. A. Effect of different transferrin forms on transferrin-receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J. Clin. Invest 1986; 78: 1538–1546
   PubMed Web of Science ®Google Scholar
• Chitambar C. R., Zivkovic Z. Uptake of gallium-67 by human leukemic cells, demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res 1987; 47: 3929–3934
   PubMed Web of Science ®Google Scholar
• Chitambar C. R., Matthaeus W. G., Antholine W. E., Graff K., O'Brien W. J. Inhibition of leukemic HL60 cell growth by transferrin-gallium, effects on ribonucleotide reductase and demonstration of drug synergy with hydroxy urea. Blood 1988; 72: 1930–1936
   PubMed Web of Science ®Google Scholar
• Chu B. C. R., Howell S. P. Differential toxicity of carrier-bound methotrexate toward human lymphocytes, marrow, and tumor cells. Biochem. Pharmacol 1981; 30: 2545–2552
   PubMed Web of Science ®Google Scholar
• Chu B. C. F., Whitely J. M. High molecular weight derivatives of methotrexate as chemotherapeutic agent. Mol. Pharmacol 1977; 13: 80–88
   PubMed Web of Science ®Google Scholar
• Chu B. C. F., Whitely J. M. Control of solid tumor metastasis with a high-molecular-weight derivative of methotrexate. J. Natl. Cancer Inst 1979; 62: 79–82
   PubMed Web of Science ®Google Scholar
• Chu B. C. F., Whitely J. M. The interaction of carrier-bound methotrexate with L1210 cells. Mol. Pharmacol 1980; 17: 382–387
   PubMed Web of Science ®Google Scholar
• Chun P. W., Brumbaugh E. E., Shireman R. B. Interaction of human low density lipoprotein and apolipoprotein-B with ternary lipid microemulsion. Biophys. Chem 1986; 25: 223–241
   PubMed Web of Science ®Google Scholar
• Colombatti M., Bisconti M., Dell'Arciprete L., Gerosa M. A., Tridente G. Sensitivity of human glioma cells to cytotoxic heteroconjugates. Int. J. Cancer 1988; 42: 441–448
   PubMed Web of Science ®Google Scholar
• Colombatti M., Dell'Arciprete L., Chignola R., Tridente G. Carrier protein-monensin conjugates: Enhancement of immunotoxin cytotoxicity and potential in tumor treatment. Cancer Res 1990; 50: 1385–1391
   PubMed Web of Science ®Google Scholar
• De Smidt P. C., van Berkel T. J. C. Prolonged serum half life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res 1990; 50: 7476–7482
   PubMed Web of Science ®Google Scholar
• Dosio F., Brusa P., Crosasso P., Arpicco S., Cartel L. Preparation, characterization, and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Controlled Release 1997; 47: 293–304
   Web of Science ®Google Scholar
• Drevs J., Hofmann I., Marmé D., Unger C., Kratz F. Superior in vivo efficacy of an acid-sensitive albumin conjugate of adriamycin compared to the parent compound in murine renal cell carcinoma. Drug Del 1998, submitted
   Web of Science ®Google Scholar
• Duncan R., Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet 1994; 27: 290–306
   PubMed Web of Science ®Google Scholar
• Duncan R., Kopeckova-Rejmanova P., Strohalm J., Hume I. C., Lloyd J. B., Kopecek J. Anticancer agents coupled to N(2-hydroxypropyl) methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer 1988; 57: 147–156
   PubMed Web of Science ®Google Scholar
• Edwards C. L., Hayes R. L. Tumor scanning with 68Ga citrate. J. Nucl. Med 1969; 10: 103–105
   PubMed Web of Science ®Google Scholar
• Eley J. G., Halbert G. W., Florence A. T. Incorporation of prednimustine into low density lipoprotein: Activity against P388 cells in tissue culture. Int. J. Pharm 1990a; 65: 219–224
   Google Scholar
• Eley J. G., Halbert G. W., Florence A. T. The incorporation of estramustine into low density lipoprotein and its activity in tissue culture. Int. J. Pharm 1990b; 63: 121
   Google Scholar
• Elliott R. L., Elliott M. C., Head J. F. Preliminary results on 11 advanced breast cancer patients treated with cisplatin complexed to human transferrin. Breast Cancer Res. Treat 1990; 16: 169
   Google Scholar
• Elliott R. L., Stjernholm R., Elliott M. C. Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer. Cancer Detect. Prev 1988; 12: 469–480
   PubMedGoogle Scholar
• Faulk W. P., Taylor C. G., Yeh C. J., McIntyre J. A. Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Mol. Biother 1990; 2: 57–60
   PubMedGoogle Scholar
• Filipowska D., Filipowska T., Morelowska B., Kazanowska W., Laudanski T., Lapinjoki S., Akerlund M., Breeze A. Treatment of cancer patients with a low-density lipoprotein delivery vehicle containing a cytotoxic drug. Cancer Chemother. Pharmacol 1992; 29: 396–400
   PubMed Web of Science ®Google Scholar
• Firestone R. A. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem 1994; 5: 105–113
   PubMed Web of Science ®Google Scholar
• Firestone R. A., Pisano J. M., Falck J. R., McPhaul M. M., Krieger M. Selective delivery of cytotoxic compounds to cells by the LDL pathway. J. Med. Chem 1984; 27: 1037–1043
   PubMed Web of Science ®Google Scholar
• Fiume L., Di Stefano G., Busi C., Mattioli A., Bonino F., Torrani-Cerenziana M., Verme G., Rapicetta M., Bertini M., Gervasi G. B. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J. Virol. Hepat 1997; 4: 363–370
   PubMed Web of Science ®Google Scholar
• Friden P. M., Walus L. R., Musso G. F., Taylor M. A., Malfroy B., Starzyk R. M. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA 1991; 88: 4771–4775
   PubMed Web of Science ®Google Scholar
• Fritzer M., Barabas K., Szüts V., Berczi A., Szekeres T., Faulk W. P., Goldenberg H. Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. Int. J. Cancer 1992; 52: 619–623
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulous D. Liposome formulations with prolonged ciriculation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 1988; 85: 6949–6953
   PubMed Web of Science ®Google Scholar
• Gabor F., Wollmann K., Theyer G., Haberl I., Hamilton G. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells. Anticancer Res 1994; 14: 1943–1950
   PubMed Web of Science ®Google Scholar
• Gal D., MacDonald P. C., Porter J. C., Simpson E. R. Cholesterol metabolism in cancer cells in monolayer culture: III. Low-density lipoprotein metabolism. Int. J. Cancer 1981a; 28: 315–319
   PubMed Web of Science ®Google Scholar
• Gal D., Ottashi M., MacDonald P. C., Buschbaum H. J., Simpson E. R. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasm. Am. J. Obstet. Gynecol 1981b; 139: 877–885
   PubMed Web of Science ®Google Scholar
• Gal D., Simpson E. R., Porter J. C., Snyder J. M. Defective internalization of low density lipoprotein in epidermoid cervical cancer cells. J. Cell Biol 1982; 92: 597–603
   PubMed Web of Science ®Google Scholar
• Ginsburg G. S., Walsh M. T., Small D. M., Atkinson D. Reassembled plasma low density lipoproteins. J. Biol. Chem 1984; 259: 6667–6673
   PubMed Web of Science ®Google Scholar
• Goldstein J. L., Brown M. S. The low-density lipoprotein pathway and its relation to artherosclerosis. Ann. Rev. Biochem 1977; 46: 897–930
   PubMed Web of Science ®Google Scholar
• Greenfield L., Johnson V. G., Youle R. L. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987; 238: 536–539
   PubMed Web of Science ®Google Scholar
• Greenfield R. S., Kaneko T., Daues A., Edson M. A., Fitzgerald K. A., Olech L. J., Grattan A., Spitalny G. L., Braslawsky G. R. In vitro evaluation of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res 1990; 50: 6600–6607
   PubMed Web of Science ®Google Scholar
• Gupta P. K., Hung C. T. Albumin microspheres II: Application in drug delivery. J. Microencapsulation 1989b; 6: 427–462
   PubMed Web of Science ®Google Scholar
• Gupta P. K., Hung C. T. Albumin microspheres I: Physiochemical characteristics. J. Microencapsulation 1989a; 6: 463–472
   PubMed Web of Science ®Google Scholar
• Hall W. A., Godal A., Juell S., Fodstad O. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J. Neurosurg 1992; 76: 838–844
   PubMed Web of Science ®Google Scholar
• Hartung G., Stehle G., Sinn H., Schrenk H. H., Heeger S., Kränzle D., Fiebig H. H., Maier-Borst W., Heene D. L., Queiβler W. Phase I-trial of a methotrexate-albumin conjugate (MTX-HSA) in cancer patients. ECCO 9, Eur. J. Cancer 1997; S249: 1129
   Google Scholar
• He X. M., Carter D. C. Atomic structure and chemistry of human serum albumin. Nature 1992; 358: 209–215
   PubMed Web of Science ®Google Scholar
• Henriksson P., Ericsson S., Stege R., Ericsson M., Rudling M., Berglund R., Angelin B. Hypocholesterolemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 1989; II: 1178–1180
   Google Scholar
• Ho Y. K., Smith R. G., Brown M. S., Goldstein J. L. Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemic cells. Blood 1978; 52: 1099–1114
   PubMed Web of Science ®Google Scholar
• Hoshino T., Misaki M., Yamamoto M., Shimizu H., Ogawa Y., Toguchi H. In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. J. Pharm. Sci 1994; 84: 216–221
   Web of Science ®Google Scholar
• Hynds S. A., Welsh J., Stewart J. M., Jack A., Soulop M., McArdle C. S., Calmann K. C., Packard C. J., Shepherd J. Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim. Biophys. Acta 1984; 795: 589–595
   PubMed Web of Science ®Google Scholar
• Isaacsohn J. L., Lees A. M., Lees R. S., Strauss H. W., Barlaikovach M., Moore T. J. Adrenal imaging with technetium-99m-labelled low density lipoproteins. Metabolism 1986; 35: 364–366
   PubMedGoogle Scholar
• Ishiguro K., Ho P. T., Sartorelli A. C. Characterization of the defect in a variant of HL-60 promyelocytic leukemia cells with reduced transferrin receptor expression. Somat. Cell. Mol. Genet 1992; 18: 45–63
   PubMedGoogle Scholar
• Iwanik M. J., Shaw K. V., Leswith B. J., Yanovich S., Shaw J. M. Preparation and interaction of a low-density lipoprotein daunomycin complex with P 388 leukemic cells. Cancer Res 1984; 44: 1206–1215
   PubMed Web of Science ®Google Scholar
• Jain R. K. Transport of molecules across tumor vaculature. Cancer Metast. Rev 1987a; 6: 559–593
   PubMed Web of Science ®Google Scholar
• Jain R. K. Transport of molecules in the tumor interstitium: A review. Cancer Res 1987b; 47: 3039–3051
   PubMed Web of Science ®Google Scholar
• Jeffries W. A., Brandon M. R., Hunt S. V., Williams A. F., Gatter K. C., Mason D. Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984; 312: 162–163
   PubMed Web of Science ®Google Scholar
• Johnson V. G., Wilson G., Greenfield L., Youle R. J. The role of the diphtheria toxin receptor in cytosol translocation. J. Biol. Chem 1988; 263: 1295–130
   PubMed Web of Science ®Google Scholar
• Keppler B. K., Lipponer K. -G., Stenzel B., Kratz F. New tumor-inhibiting ruthenium complexes. Metal Complexes in Cancer Chemotherapy, B. K. Keppler. Verlag Chemie, VCH, Weinheim 1993; 187–220, Verlag Chemie, VCH
   Google Scholar
• Kerr D. J., Hynds S. A., Shepherd J., Packard C. J., Kaye S. B. Comparative cellular uptake an cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers. Biochem. Pharmacol 1988; 37: 3981–3986
   PubMed Web of Science ®Google Scholar
• Kohgo Y., Kondo H., Kato J., Sasaki K., Tsushima N., Nishisato T., Hirayama M., Fujikawa K., Shintani N., Mogi Y. Kinetics of internalization and cytotoxicity of transferrin-neocarzinostatin conjugate in human leukemia cell line, K562. Japan. J. Cancer Res 1990; 81: 91–99
   PubMedGoogle Scholar
• Kohgo Y., Niitsu Y., Nishisato T., Urushizaki Y., Kondo H., Fukushima M., Tsushima M., Urushizaki I. Transferrin receptor of tumor cells—potential tools for diagnosis and treatment of malignancies. Proteins of Iron Storage and Transport, G. Spik, J. Montreuil, R. R. Crichton, J. Mazurier. Elsevier Science Publishers, Amsterdam 1985; 155–169
   Google Scholar
• Kornfeld S. B., Leonard J. E., Mullen M. D., Taetle R. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas. Cancer Res 1991; 51: 4316–4322
   PubMedGoogle Scholar
• Kratz F. Interactions of antitumour metal complexes with serum proteins. Perspectives for anticancer drug development. A review. Metal Complexes as Antitumour Agents, B. K. Keppler. Verlag Chemie Weinhein. 1993; 392–429
   Google Scholar
• Kratz F. Drug targeting in der antitumoralen Chemotherapie. Anti-gene und Rezeptoren als Angriffspunkte einer selektiven Chemotherapie. Pharmazie in unserer Zeit 1995; 24: 14–26
   PubMedGoogle Scholar
• Kratz F., Beyer U., Coltery P., Lechenault F., Cazabat A., Schumacher P., Falken U., Linger C. Preparation, characterization, and in vitro efficacy of albumin conjugates of doxorubicin. Biol. Pharm. Bull 1998a; 21: 56–61
   PubMed Web of Science ®Google Scholar
• Kratz F., Beyer U., Roth T., Schütte M. T., Unold A., Fiebig H. H., Unger C. Albumin conjugates of the anticancer drug chlorambucil: Synthesis, characterization, and in vitro efficacy. Arch. Pharm. Pharm. Med. Chem 1998b; 331: 47–53
   PubMed Web of Science ®Google Scholar
• Kratz F., Beyer U., Roth T., Tarasova N., Collery P., Lechenault F., Cazabat A., Schumacher P., Unger C., Falken U. Transferrin conjugates of doxorubicin: Synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci 1998c; 87: 338–346
   PubMed Web of Science ®Google Scholar
• Kratz F., Beyer U., Schumacher P., Krüger M., Zahn H., Roth T., Fiebig H. H., Unger C. Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates. Bioorg. Med. Chem. Lett 1997a; 7: 617–622
   Web of Science ®Google Scholar
• Kratz F., Fichtner I., Beyer U., Schumacher P., Roth T., Fiebig H. H., Unger C. Antitumor activity of acid labile transferrin and albumin doxorubicin conjugates in vitro and in vivo human tumour xenograft models. Eur. J. Cancer 1997b; 33: 784
   Web of Science ®Google Scholar
• Kratz F., Hartmann M., Keppler B. K., Messori L. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J. Biol. Chem 1994a; 269: 2581–2588
   PubMed Web of Science ®Google Scholar
• Kratz F., Keppler B. K., Hartmann M., Messori L., Berger M. R. Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms in a human colon cancer cell line. Metal-Based Drugs 1996; 3: 15–23
   PubMedGoogle Scholar
• Kratz F., Keppler B. K., Messori L., Smith C., Baker E. N. Protein-binding properties of two antitumour Ru(III) complexes to human apotransferrin and apolactoferrin. Metal-based Drugs 1994b; 1: 169–173
   PubMedGoogle Scholar
• Kratz F., Mulinacci N., Messori L., Bertini I., Keppler B. K. Kinetic, spectroscopic and LPLC studies of the interactions of antitumour ruthenium(III) complexes with serum proteins. Metal Ions in Biology and Medicine. John Libbey Limited Eurotext, John Paris 1992; Vol. 2: 69–74
   Google Scholar
• Kratz F., Roth T., Fiebig H. H., Unger C. Superior in vivo efficacy of an acid-sensitive albumin conjugate of doxorubicin in two human xenograft models. Annual Congress of the German and Swiss Pharmaceutical Society, Zurich, Switzerland, 1997c; P55
   Google Scholar
• Kratz F., Roth T., Fichtner I., Fiebig H. H., Unger C. Development of antitumor protein and polymer conjugates using in vitro and in vivo tumor xenograft models. Relevance of Tumor Models for Anticancer Drug Development, Contribution to Oncology, H. H. Fiebig. Karger Verlag, Basel, Switzerland 1998d, in press
   Google Scholar
• Kratz F., Schutte M. T. Anticancer metal complexes and tumor targeting strategies. Cancer J 1998; 11: 176–181
   Web of Science ®Google Scholar
• Krieger M., Brown M. S., Faust J. R., Goldstein J. L. Replacement of endogenous cholesteryl esters of low density lipoprotein with exogenous cholesteryl linoleate. J. Biol. Chem 1978; 253: 4093–4101
   PubMed Web of Science ®Google Scholar
• Kritchevsky S. B., Wilcosky T. C., Morris D. L., Truong K. N., Tyroler H. A. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 1991; 51: 3198–3203
   PubMed Web of Science ®Google Scholar
• Krüger M., Beyer U., Schumacher P., Unger C., Zahn H., Kratz F. Synthesis and stability of four maleimide derivatives of the anticancer drug doxorubicin for the preparation of chemoimmunoconjugates. Chem. Pharm. Bull 1997; 47: 399–401
   Google Scholar
• Laurie S. M., Robbins A. R. A toxin-resistant mouse L-cell mutant defective in protein transport along the secretory pathway. J. Cell Physiol 1991; 147: 215–223
   PubMed Web of Science ®Google Scholar
• Lemieux P., Pagé M., Noel C. In vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate. In Vivo 1992; 6: 621–628
   PubMedGoogle Scholar
• Lombardi P., Norata G., Maggi F. M., Canti G., Franco P. O., Nicolin A., Capatano A. L. Assimilation of LDL by experimental tumours in mice. Biochim. Biophys. Acta 1989; 1003: 301–306
   PubMed Web of Science ®Google Scholar
• Lundberg B. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res 1987; 47: 4105–4108
   PubMed Web of Science ®Google Scholar
• Lundberg B. Assembly of prednimustine low-density lipoprotein complexes and their cytotoxic activity in tissue culture. Cancer Chemother. Pharmacol 1992; 29: 241–247
   PubMed Web of Science ®Google Scholar
• Lundberg B., Suominen L. Preparation of biologically active analogs of serum low density proteins. J. Lipid Res 1984; 25: 550–558
   PubMed Web of Science ®Google Scholar
• Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles macromolecular prodrugs. Crit. Rev. Ther. Drug Carrier Sys 1989; 6: 193–210
   PubMed Web of Science ®Google Scholar
• Masquelier M., Vitols S., Peterson C. Low-density lipoprotein as a carrier antitumoral drugs: In vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res 1986; 46: 3842–3847
   PubMed Web of Science ®Google Scholar
• Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins of the antitumor agent smancs. Cancer Res 1986; 46: 6387–6392
   PubMed Web of Science ®Google Scholar
• Means G. E., Feeney R. E. Chemical modification of proteins: History and application. Bioconjugate Chem 1990; 1: 2–12
   PubMed Web of Science ®Google Scholar
• Messori L., Kratz F. Transferrin-from inorganic biochemistry to medicine. Metal-based Drugs 1994; 1: 161–167
   PubMedGoogle Scholar
• Mider G. B., Tesluk H., Morton J. J. Effects of Walker carcinoma 256 on food intake, body weight, and nitrogen metabolism of growing rats. Acta Union Int. Contra Cancrum 1948; 6: 409–420
   Google Scholar
• Miller S. R., Tartter P. I., Papatestas A. E., Slater G., Aufses A. H., Jr. Serum cholesterol and human colon cancer. J. Natl. Cancer Inst 1981; 67: 297–300
   PubMed Web of Science ®Google Scholar
• Morimoto Y., Fujimoto S. Albumin microspheres as drug carriers. Crit. Rev. Then Drug Carrier Syst 1985; 2: 19–63
   PubMedGoogle Scholar
• Mukherjee S., Grosh R. N., Maxfield F. R. Endocytosis. Physiol. Rev 1997; 77: 759–803
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A., Mukhopadhyay B., Basu S. K. Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery. FEBS Lett 1995; 376: 95–98
   PubMed Web of Science ®Google Scholar
• Neville D. M., Jr, Srinavasachar K., Stone R., Scharff J. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J. Biol. Chem 1989; 264: 14653–14661
   PubMed Web of Science ®Google Scholar
• Norata G., Canti G., Ricci L., Nicolin A., Trezzi E., Capatano A. L. In vivo assimilation of low-density lipoproteins by a fibrosarcoma tumour cell line in mice. Cancer Lett 1984; 25: 203–208
   PubMed Web of Science ®Google Scholar
• Ohkawa K., Hatano T., Tsukada Y., Matsuda M. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro. Br. J. Cancer 1993a; 67: 274–278
   PubMed Web of Science ®Google Scholar
• Ohkawa K., Hatano T., Yamada K., Joh K., Takada K., Tsukada Y., Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 1993b; 53: 4238–4242
   PubMed Web of Science ®Google Scholar
• O'Keefe D. O., Draper R. K. Characterization of a transferrin-diphtheria toxin conjugate. J. Biol. Chem 1985; 260: 932–937
   PubMed Web of Science ®Google Scholar
• O'Keefe D. O., Draper R. K. Two pathways of transferrin recycling evident in a variant of mouse LMTK-cells. Somat. Cell. Mol. Genet 1988; 14: 473–487
   PubMedGoogle Scholar
• Partridge W. M. Brain drug delivery and blood-brain barrier transport. Drug Del 1996; 3: 99–115
   Google Scholar
• Peters T., Jr. Serum albumin. Adv. Protein. Chem 1985; 37: 161–245
   PubMedGoogle Scholar
• Peterson C., Vitols S., Rudling M., Blomgren H., Edsmyr F., Skoog L. Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med. Oncol. Tumor Pharmacother 1985; 2: 143–147
   PubMedGoogle Scholar
• Porta C., Moroni M., Nastasi G., Invernizzi R., Bobbio-Pallavicini E. Hypocholesterolemia and acute myeloid leukemia (AML). Haematologica 1991; 76: 348
   PubMedGoogle Scholar
• Raso V., Basala M. A highly cytotoxic human transferrin-ricin. A chain conjugate used to select receptor-modified cells. J. Biol. Chem 1984; 259: 1143–1149
   PubMed Web of Science ®Google Scholar
• Raso V., Lawrence J. Carboxylic ionophores enhance the cytotoxic potency of ligand- and antibody-delivered ricin A chain. J. Exp. Med 1984; 160: 1234–1240
   PubMed Web of Science ®Google Scholar
• Raso V., Watkins S. C., Slayter H., Fehrmann C. Intracellular pathway of ricin A chain cytotoxins. Ann. N. Y. Acad. Sci 1987; 507: 172–186
   PubMed Web of Science ®Google Scholar
• Roth T., Fiebig H. H., Eckert C., Spitzmüller B., Beyer U., Schumacher P., Unger C., Kratz F. In vitro antitumor efficacy of acid labile transferrin conjugates of doxorubicin in ten human tumor xenografts. Proc. Amer. Assoc. Cancer Res 1997; 38: 2898
   Google Scholar
• Rybak S. M., Saxena S. K., Ackerman E. J., Youle R. J. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J. Biol. Chem 1991; 266: 21202–21207
   PubMed Web of Science ®Google Scholar
• Sands H., Jones P. L., Shah A. S., Palme D., Vessella R. L., Gallagher B. M. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human clouser and renal cell xenografts. Cancer Res 1988; 48: 188–193
   PubMed Web of Science ®Google Scholar
• Schilling U., Friedrich A., Sinn H., Schrenk H. H., Clorius J. H., Maier-Borst W. Design of compounds having enhanced tumour uptake, using serum albumin as a carrier-Part 2. Nucl. Med. Biol 1990; 19: 685–695, Int. J. Rod. Appl. Instrum. B:
   Web of Science ®Google Scholar
• Schüler J., Fiebig H. H., Sausville E. A., Burger A. M. (1997) Characterization of vascular permeability in human tumor xenografts-identification of suitable tumor models to evaluate polymer conjugates. Int. Symposium “Relevance of Tumor Models for Anticancer Drug Development”. 10, 1997. Tumor Biology Center, Freiburg, FRG, 15–17, P6
   Google Scholar
• Seymour L. W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Sys 1992; 9: 135–187
   PubMed Web of Science ®Google Scholar
• Seymour L. W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., Duncan R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular carrier. Eur. J. Cancer 1995; 31A: 766–770
   PubMed Web of Science ®Google Scholar
• Sinn H., Schrenk H. H., Friedrich A., Schilling U., Maier-Borst W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Nucl. Med. Biol 1990; 17: 819–827, Int. J. Rad. Appl. Instrum. B, Part 1
   Web of Science ®Google Scholar
• Smith C. A., Sutherland-Smith A. J., Keppler B. K., Kratz F., Baker E. N. Binding of ruthenium(III) anti-tumor drugs to human lactoferrin by high resolution X-ray crystallographic structure analysis. J. Bioinorg. Chem 1996; 1: 424–431
   Web of Science ®Google Scholar
• Som P., Oster Z. H., Matsui K., Guglelmi G., Persson B. R. R., Pellettieri M. L., Srivastava S. C., Richards P., Atkins H. L., Brill A. B. Ru-97-transferrin uptake in tumor and abscess. Eur. J. Nucl. Med 1983; 8: 491–494
   PubMedGoogle Scholar
• Srivastava S. C., Richards P., Meinken G. E., Larson S. M., Grunbaum Z. Tumor uptake of radioruthenium compounds. Radiopharmaceuticals: Structure-Activity Relationship, R. Spencer. Grune and Stratton, New York 1981; 207–223
   Google Scholar
• Stehle G., Sinn H., Wunder A., Schrenk H. H., Schütt S., Heene D. L., Maier-Borst W. The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anti-Cancer Drugs 1997a; 8: 677–685
   PubMed Web of Science ®Google Scholar
• Stehle G., Sinn H., Wunder A., Schrenk H. H., Stewart J. C. M., Hartung G., Maier-Borst W., Heene D. L. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol 1997; 26: 77–100
   PubMed Web of Science ®Google Scholar
• Stehle G., Wunder A., Sinn H., Schrenk H. H., Schütt S., Frei E., Hartung G., Maier-Borst W., Heene D. L. Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats. Anti-Cancer Drugs 1997b; 8: 835–844
   PubMed Web of Science ®Google Scholar
• Stjernholm R. L. Platinum bound to transferrin for use in the treatment of breast tumors. US patent 4590001 A 20, 1986, May 1986
   Google Scholar
• Stjernholm R., Warner F. W., Robinson J. W., Ezekiel E., Katayama N. Binding of platinum to human transferrin. Bioinorg. Chem 1978; 9: 277–280
   PubMedGoogle Scholar
• Subr V., Strohalm J., Ulbrich K., Duncan R. Polymers containing enzymatically degradable bonds. XII. Release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymers. J. Controlled Release 1992; 18: 123–132
   Web of Science ®Google Scholar
• Sun I. L., Sun E. E., Crane F. L., Morre D. J., Faulk W. P. Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates. Biochim. Biophys. Acta 1992; 1105: 84–88
   PubMed Web of Science ®Google Scholar
• Sutherland R., Delia D., Schneider C., Newmann R., Kemshead J., Greaves M. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. USA 1980; 78: 4515–4519
   Web of Science ®Google Scholar
• Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition and tumor localization of mitomycin C dextran conjugates in mice. Pharm. Res 1987; 4: 293–300
   PubMed Web of Science ®Google Scholar
• Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res 1990; 7: 339–346
   PubMed Web of Science ®Google Scholar
• Takakura Y., Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: Macromolecular prodrugs. Crit. Rev Oncol. Hematol 1994; 18: 207–231
   Web of Science ®Google Scholar
• Tanaka T., Kaneo Y., Iguchi S. Properties of mitomycin C-protein conjugates in vitro and in vivo. Bioconjugate Chem 1991; 2: 261–269
   PubMed Web of Science ®Google Scholar
• Tanaka T., Kaneo Y., Miyashita M. Synthesis of transferrin-mitomycin C conjugate as a receptor-mediated drug targeting system. Biol. Pharm. Bull 1996; 19: 114–111
   PubMedGoogle Scholar
• Tanaka T., Kaneo Y., Shiramoto S., Iguchi S. The disposition of serum proteins as drug carriers in mice bearing sarcoma 180. Biol. Pharm. Bull 1993; 16: 1270–1275
   PubMed Web of Science ®Google Scholar
• Testa U., Pelosi E., Peschle C. The transferrin receptor. Crit. Rev. Oncogenesis 1993; 4: 241–276
   PubMed Web of Science ®Google Scholar
• Trouet A., Masquelier M., Baurain R., Campeneere D. D.-D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolaseed, as required for a lysosomotropic drug carrier conjugate: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 1982; 79: 626–629
   PubMed Web of Science ®Google Scholar
• Trowbridge I. S. Transferrin receptor as a potential therapeutic agent. Prog. Allergy 1988; 45: 121–146
   PubMedGoogle Scholar
• Trowbridge I. S., Omary M. B. Human cell surface glycoprotein related to the cell proliferation is the receptor for transferrin. Proc. Natl. Sci. USA 1981; 78: 3039–3043
   PubMed Web of Science ®Google Scholar
• Urushizaki I. Targeting effect of transferrin-neocarzinostatin conjugate by receptor-mediated endocytosis. Nippon Rinsho-Japan. J. Clin. Med 1989; 47: 1423–1431
   PubMedGoogle Scholar
• Versluis A. J., van Geel P. J., Oppelaar H., van Berkel T. J. C., Bijsterbosch M. K. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br. J. Cancer 1996; 74: 525–532
   PubMed Web of Science ®Google Scholar
• Vitols S. Uptake of low-density lipoprotein by malignant cells-possible therapeutic applications. Cancer Cells 1991; 3: 488–495
   PubMed Web of Science ®Google Scholar
• Vitols S., Gahrton G., Öst Å., Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 1984; 63: 1186–1193
   PubMed Web of Science ®Google Scholar
• Vitols S., Söderberg-Reid K., Masquelier M., Sjöström B., Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br. J. Cancer 1990; 62: 724–729
   PubMed Web of Science ®Google Scholar
• Wagner E., Curiel D., Cotten M. Delivery of drugs, proteins and genes into cells using transferrin as ligand for receptor-mediated endocytosis. Adv. Drug Del. Rev 1994; 14: 113–135
   Web of Science ®Google Scholar
• Walsh M. T., Ginsburg G. S., Small D. M., Atkinson D. Apo B-lecithin-cholesterol ester complexes: Reassembly of low density lipoprotein. Arteriosclerosis 1982; 2: 445a
   Google Scholar
• Ward S. G., Taylor R. C. Anti-tumor activity of the main-group metallic elements: Aluminium, gallium, thallium, germanium, lead, antimony and bismuth. Metal-based Antitumor Drugs, M. F. Gielen. Freund Publishing House Ltd., London 1988, Chapter 1
   Google Scholar
• Warner F. W., Demanuelle M., Stjernholm R., Cohn I., Baddley W. H. Response to transferrin bound iron to treatment of rat lymphosarcoma with cisdichlorodiammine-platinum(II). J. Clin. Hematol. Oncol 1977; 7: 180–189
   Google Scholar
• White S., Taetle R., Seligman P. A., Rutherford M., Trowbridge I. S. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects. Cancer Res 1991; 50: 6295–6301
   Web of Science ®Google Scholar
• Wunder A., Stehle G., Sinn H., Schrenk H. H., Hoff-Biederbeck D., Bader F., Friedrich E. A., Peschke P., Maier-Borst W., Heene D. L. Enhanced albumin uptake by rat tumors. Int. J. Oncol 1997; 11: 497–507
   PubMed Web of Science ®Google Scholar
• Yeh C. J., Faulk W. P. Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clin. Immunol. Immunopath 1984; 32: 1–11
   PubMedGoogle Scholar
• Yuan F., Deilian M., Fukumura D., Leuning M., Berk D. A., Torchilin V. P., Jain R. K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752–3756
   PubMed Web of Science ®Google Scholar
• Zyada L. E., Hassan H. T., Rees J. K. H., Ragab M. H. The relation between hypocholesterolemia and degree of maturation of in acute myeloid leukemia. Hematol. Oncol 1990; 8: 65–69
   PubMed Web of Science ®Google Scholar